Fractyl Health, Inc. GUTS
0.99 USD +0.09 (+9.76%)
Regular-session close
0.97 -0.03 -2.58%
Pre-market · Nov 17, 8:09 AM ET
0.92 Day range 1.08
0.80 52-week range 29.34
- YTD
- -96.24%
- 1 year
- -93.44%
Benzinga news
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Akanda (NASDAQ:AKAN) stock rose 42.6% to $1.94 during Monday's regular session. The market value of their outstanding shares is at $3.5 million. CEL-SCI (AMEX:CVM) shares increased by 30.46%…benzinga.com Canaccord Genuity Maintains Buy on Fractyl Health, Raises Price Target to $40 Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $39 to $40.
benzinga.com HC Wainwright & Co. Maintains Buy on Fractyl Health, Raises Price Target to $24 HC Wainwright & Co. analyst Joseph Pantginis maintains Fractyl Health (NASDAQ:GUTS) with a Buy and raises the price target from $8 to $24.
benzinga.com Fractyl Health Q3 EPS $(1.07) Beats $(1.51) Estimate Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.51) by 29.14 percent. This is a 87.44 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…benzinga.com Fractyl Health Expands Revita Patent Portfolio Ahead Of Planned FDA De Novo Submission Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today…
benzinga.com Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027Workforce…
benzinga.com Canaccord Genuity Maintains Buy on Fractyl Health, Lowers Price Target to $39 Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and lowers the price target from $96 to $39.
benzinga.com Morgan Stanley Maintains Equal-Weight on Fractyl Health, Lowers Price Target to $4 Morgan Stanley analyst Michael Ulz maintains Fractyl Health (NASDAQ:GUTS) with a Equal-Weight and lowers the price target from $24 to $4.
